(Source: DGCIS Kolkata)

- (b) The Central Government provides the available necessary help to the State Government in implementing their projects which also help in generating more employment.
- (c) The Department of Pharmaceuticals has at present no plan for acquiring any land for Pharma City.
- (d) The Department is at present implementing a scheme for Cluster Development Programme for Pharma Sector (CDP-PS) for financing common facilities in Pharma Clusters in the country. Through this scheme, the government proposes to finance common facilities of these clusters/parks.

Passing on the benefit of price cap on stents to patients

2460. SHRI K. RAHMAN KHAN: Will the Minister of CHEMICALS AND FERTILIZERS be pleased to state:

- (a) whether capping the price of cardiac stents last year by NPPA by almost 85 per cent has resulted in reduction of prices of overall angioplasty procedure by 8 to 18 per cent only;
- (b) whether Government will conduct a study to find out the reasons behind the failure of fall in the prices of the angioplasty procedure despite reduction in the prices of the cardiac stents by 85 per cent; and
- (c) whether Government will evolve a monitoring system to ensure that the benefit of capping of cardiac stent prices reaches the poor in real sense?

THE MINISTER OF STATE IN THE MINISTRY OF CHEMICALS AND FERTILIZERS (SHRI MANSUKH L. MANDAVIYA): (a) National Pharmaceutical Pricing Authority (NPPA) *vide* its notification S. O. 412 (E), dated 13th February, 2017 fixed the ceiling price of the coronary stents. Institutions such as hospitals/nursing homes/

clinics utilizing Coronary Stents for angioplasty are bound to abide by the ceiling prices fixed by the Government for coronary stents. As per the study conducted by IQVIA services (a leading global provider of information, innovative technology solutions and contract research services formed through the merger of IMS Health and Quintiles), and sponsored by the Advanced Medical Technology Association (AdvaMed), a trade association, it is stated that reduction in stent price resulted in 8-18% reduction in overall angioplasty procedure cost for the patients.

- (b) The Government has no such proposal at present.
- (c) On examination of data relating to stents, it is found that the prices of catheter, balloon catheter and guidewire are exorbitantly high. Because of the exorbitant prices of catheters and balloons, which are many times higher than the stent prices itself, the objective of price capping of stents gets diluted. The 'procedure charges' and 'doctors fees' which the hospitals are billing to the patients for angioplasty is said to have increased as per feedback. Notices have been issued to some hospitals. Moreover, healthcare institutions which are performing angioplasty and billing the patients have been instructed to mention cost of cardiac catheters, balloon catheter and guide wire separately along with their respective brand name, if any, name of the company, batch number and specifications in order to bring in greater transparency in the billing and monitoring of compliance with the Maximum Retail Prices (MRPs) by the NPPA. The Government is effectively monitoring the implementation of ceiling prices fixed for coronary stents.

Controlling the prices of life-saving drugs

2461. SHRI DARSHAN SINGH YADAV:

SHRIMATI RAJANI PATIL:

SHRI P. BHATTACHARYA:

Will the Minister of CHEMICALS AND FERTILIZERS be pleased to state:

- (a) the details of generic medicines available for treating cancer and other lifethreatening diseases in the country;
- (b) whether Government is under pressure for keeping the prices of cancer medicines at par with those medicines made by American manufacturers;
 - (c) if so, the reaction of Government thereon; and
- (d) the steps being taken by Government to control the prices of such lifesaving drugs?